Keyphrases
Temozolomide
100%
Efficacy Trial
100%
Clinical Efficacy
100%
Newly Diagnosed
100%
Anaplastic Oligodendroglioma
100%
Response Rate
28%
Chemotherapy
28%
Tumor
28%
Neurological Function
28%
Initial Treatment
28%
Karnofsky Performance Status
28%
Time to Tumor Progression
28%
Treatment Duration
14%
Radiotherapy
14%
Combination Therapy
14%
Tumor Progression
14%
Median Time
14%
Clinical Response
14%
Optimal Duration
14%
Alkylating Agents
14%
MRI Evaluation
14%
Objective Response
14%
Hematotoxicity
14%
Objective Response Rate
14%
Long Progression-free Survival
14%
Starting Dose
14%
Medicine and Dentistry
Temozolomide
100%
Oligodendroglioma
100%
Tumor Progression
42%
Neoplasm
28%
Karnofsky Performance Status
28%
Magnetic Resonance Imaging
14%
Radiation Therapy
14%
Combination Therapy
14%
Treatment Duration
14%
Progression Free Survival
14%
Alkylating Antineoplastic Agent
14%
Nervous System Physiology
14%
Pharmacology, Toxicology and Pharmaceutical Science
Oligodendroglioma
100%
Temozolomide
100%
Tumor Growth
42%
Chemotherapy
28%
Neoplasm
28%
Combination Therapy
14%
Progression Free Survival
14%
Alkylating Agent
14%
Neuroscience
Temozolomide
100%
Oligodendroglioma
100%
Magnetic Resonance Imaging
14%
Alkylating Antineoplastic Agent
14%
Radiation Therapy
14%
Veterinary Science and Veterinary Medicine